Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer

奥沙利铂 医学 化疗 内科学 不利影响 临床终点 胃肠病学 癌症 吉西他滨 随机对照试验 结直肠癌
作者
Ting Zhang,Chengpei Zhu,Nan Zhang,Longhao Zhang,Shanshan Wang,Ziyu Xun,Yiyao Xu,Xiaobo Yang,Xin Lü,Haitao Zhao
出处
期刊:International Immunopharmacology [Elsevier]
卷期号:129: 111642-111642 被引量:2
标识
DOI:10.1016/j.intimp.2024.111642
摘要

To compare the treatment efficacy and safety of lenvatinib and programmed cell death 1 (PD-1) inhibitor combined with oxaliplatin plus gemcitabine (Gemox) chemotherapy or hepatic arterial infusion chemotherapy (HAIC) for patients with advanced biliary tract cancer (BTC). This study involved 86 patients with advanced BTC receiving PD-1 inhibitor and lenvatinib combined with HAIC (P-L-H group) or Gemox chemothrapy (P-L-G group). Propensity score matching (PSM) (1:1) analysis was used to balance potential bias. The primary endpoints were overall survival (OS) and progression-free survival (PFS), whereas the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and safety. After PSM, a total of 60 patients were enrolled with 30 in the P-L-G group and 30 in the P-L-H group. The median PFS was significantly longer with P-L-G group (13.7 versus 6.0 months, p < 0.0001) than with the P-L-H group. The median OS was 23.8 months in the P-L-G group versus 11.6 months in the P-L-H group (p < 0.0001). Patients in the P-L-G group exhibited a better ORR (73.3 % vs 30 %, p = 0.002) compared to the P-L-H group. The DCR was the same in both groups, 96.7 %, respectively. The P-L-G group had a higher incidence of grade 3–4 AEs than the P-L-H group. However, there was no significant difference in the any grade or grade 3–4 of AEs between the two groups. PD-1 inhibitor plus lenvatinib and Gemox are promising first-line regimens for the treatment of advanced BTC in the multicenter retrospective real-world study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我不秃头发布了新的文献求助10
1秒前
整齐星月完成签到,获得积分20
1秒前
bkagyin应助yiwei采纳,获得10
2秒前
2秒前
pp-doctor发布了新的文献求助10
3秒前
4秒前
4秒前
思源应助科研通管家采纳,获得10
5秒前
天天快乐应助科研通管家采纳,获得10
5秒前
英俊的铭应助科研通管家采纳,获得10
5秒前
领导范儿应助科研通管家采纳,获得10
5秒前
充电宝应助科研通管家采纳,获得10
5秒前
慕青应助科研通管家采纳,获得10
5秒前
传奇3应助科研通管家采纳,获得10
5秒前
可爱的函函应助北城采纳,获得10
6秒前
L77完成签到,获得积分0
7秒前
我不秃头完成签到,获得积分10
7秒前
田様应助jaslek采纳,获得10
8秒前
8秒前
王炸炸完成签到,获得积分10
10秒前
10秒前
mogui发布了新的文献求助10
10秒前
深情安青应助陈淑玲采纳,获得10
11秒前
Han完成签到,获得积分10
12秒前
ZZY发布了新的文献求助10
12秒前
皆空发布了新的文献求助10
12秒前
禾斗科完成签到,获得积分10
13秒前
情怀应助水水水采纳,获得10
13秒前
13秒前
大头完成签到 ,获得积分10
13秒前
bolysu完成签到,获得积分10
13秒前
斯文败类应助温柔的代曼采纳,获得10
15秒前
55完成签到,获得积分10
15秒前
d.zhang发布了新的文献求助10
15秒前
Dream点壹完成签到,获得积分10
16秒前
hanchangcun完成签到,获得积分20
18秒前
bai发布了新的文献求助10
18秒前
FashionBoy应助ZZY采纳,获得10
18秒前
chawenxian2025完成签到,获得积分10
18秒前
叶落无痕、完成签到,获得积分10
19秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3148361
求助须知:如何正确求助?哪些是违规求助? 2799495
关于积分的说明 7835018
捐赠科研通 2456710
什么是DOI,文献DOI怎么找? 1307424
科研通“疑难数据库(出版商)”最低求助积分说明 628154
版权声明 601655